Subject(s)
Angina, Unstable/metabolism , Angina, Unstable/physiopathology , Anticholesteremic Agents/pharmacology , Anticholesteremic Agents/therapeutic use , Simvastatin/pharmacology , Simvastatin/therapeutic use , Adult , Aged , Electrocardiography , Female , Humans , Hyperlipidemias/drug therapy , Lipid Peroxidation/drug effects , Male , Middle AgedABSTRACT
AIM: To evaluate effects of fozinopril on basic manifestations of metabolic syndrome in women with moderate and severe arterial hypertension (AH). Material and methods. Sixty women with AH aged 45 to 65 years entered the trial. Mean duration of the disease was 11 years. Arterial pressure (AP), carbohydrate, lipid and purin metabolism, lipid peroxidation, erythrocytic membranes resistance were examined before the trial and followed up for 6 months of the treatment. RESULTS: Fozinopril significantly reduced systolic and diastolic AP. A 6-month course of the drug brought target AP in 85.4% examinees, a good response was achieved in 96.4%. The treatment also significantly reduced the levels of insulin, C-peptide, triglycerides, increased content of HDLP cholesterol, relieved insulin resistance. Fozinopril demonstrated antioxidant, membrane stabilizing and hypouricemic efficacy. CONCLUSION: High antihypertensive efficacy and a positive action on basic manifestations of metabolic disorders allow us to recommend fozinopril as a basic drug for treatment of women with moderate and severe AH concurrent to insulin resistance syndrome.
